An Open-Label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia Receiving Standard of Care, Expectant Management
Latest Information Update: 15 Jan 2026
At a glance
- Drugs CBP-4888 (Primary)
- Indications Preeclampsia
- Focus Adverse reactions
- Sponsors Comanche Biopharma
Most Recent Events
- 22 Dec 2025 Status changed from not yet recruiting to recruiting.
- 15 Dec 2025 Status changed from planning to not yet recruiting.
- 22 Jan 2024 New trial record